Zobrazeno 1 - 10
of 932
pro vyhledávání: '"CD155"'
Autor:
Popa-Navarro Xitlally, Avilés-Salas Alejandro, Hernández-Pedro Norma, Orozco-Morales Mario, Caballé-Pérez Enrique, Castillo-Ruiz Cesar, Lucio-Lozada José, Barrios-Bernal Pedro, Hernandez-Martinez Juan-Manuel, Arrieta Oscar
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background CD155 is a transmembrane protein that inhibits antitumor immune response and represents a predictor of worse prognosis in non-small-cell lung cancer (NSCLC). However, it remains unexplored its association with clinical characteris
Externí odkaz:
https://doaj.org/article/1ebedd5e333e4f3c914155199daf9952
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-7 (2024)
Abstract Background Imbalanced immune responses are involved in developing preeclampsia (PE). We wish to explore the expression and potential changes of immune checkpoint molecules TIGIT, CD226 and CD155 in PE patients. Methods The expression of the
Externí odkaz:
https://doaj.org/article/38c7dce5ca2745f58739fe846f06e10b
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic. Therefore, it is urgent to elucidate the mechanisms unde
Externí odkaz:
https://doaj.org/article/c7579c996dda4e3597420d4d33bdda20
Publikováno v:
Beni-Suef University Journal of Basic and Applied Sciences, Vol 12, Iss 1, Pp 1-8 (2023)
Abstract Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are pro
Externí odkaz:
https://doaj.org/article/186e0118cb78472bbb4b9d15c1578c2d
Publikováno v:
World Journal of Surgical Oncology, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and
Externí odkaz:
https://doaj.org/article/840b6a7fde6a4e0db92c7cd5a25b6d3f
Autor:
Neslihan Cabioglu, Aysel Bayram, Selman Emiroglu, Semen Onder, Huseyin Karatay, Gizem Oner, Mustafa Tukenmez, Mahmut Muslumanoglu, Abdullah Igci, Adnan Aydiner, Pinar Saip, Ekrem Yavuz, Vahit Ozmen
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibition, combined with novel biomarkers, may provide alternative pathways for treating chemotherapy-resistant triple-negative breast cancer (TNBC). This study investigates the expression of new immune checkpoint recepto
Externí odkaz:
https://doaj.org/article/6c28fe24519d4ea38e3d5b9e892ea461
Autor:
Xue Liu, Chenyang Xu, Tianwei Guo, Shenghua Zhan, Qiuying Quan, Mengsi Li, Ziyi Wang, Xueguang Zhang, Lingchuan Guo, Lei Cao
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionCD155 is recently emerging as a promising target in malignancies. However, the relationship between CD155 expression and tumor microenvironment (TME) cell infiltration in gastric adenocarcinoma (GAC) has rarely been clarified.MethodsWe me
Externí odkaz:
https://doaj.org/article/d2c78d56fedc4aa297e66238deacd8d4
Autor:
Huixian Xin, Yuchen Liu, Pengxiang Chen, Tianwen Yin, Meijie Wang, Tianyu Liu, Zhihua Wen, Yufeng Cheng
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-16 (2022)
Abstract The expression of CD155 has been observed to increase in various human cancers, but its role in the development of esophageal cancer (EC) is unclear. Radiotherapy is one of the primary therapeutic options for EC. However, radioresistance is
Externí odkaz:
https://doaj.org/article/bc2c78198ecc4b65970fc48d21d2b4a1
Autor:
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, Séverine Guiu, Angélique Bobrie, William Jacot
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundT cell immunoreceptor with Ig and ITIM domains (TIGIT) interacts with poliovirus receptor (PVR) to contribute to cancer immune escape. Recently, TIGIT and PVR have been identified as promising immunotherapy targets. Their gene expression is
Externí odkaz:
https://doaj.org/article/132cc83966eb4a94bf18c7d1697ca996
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.